It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Caspase-4 (CASP4) is a member of the inflammatory caspase subfamily and promotes inflammation. Here, we report that CASP4 in lung adenocarcinoma cells contributes to both tumor progression via angiogenesis and tumor hyperkinesis and tumor cell killing in response to high interferon (IFN)-γ levels. We observe that elevated CASP4 expression in the primary tumor is associated with cancer progression in patients with lung adenocarcinoma. Further, CASP4 knockout attenuates tumor angiogenesis and metastasis in subcutaneous tumor mouse models. CASP4 enhances the expression of genes associated with angiogenesis and cell migration in lung adenocarcinoma cell lines through nuclear factor kappa-light chain-enhancer of activated B cell signaling without stimulation by lipopolysaccharide or tumor necrosis factor. CASP4 is induced by endoplasmic reticulum stress or IFN-γ via signal transducer and activator of transcription 1. Most notably, lung adenocarcinoma cells with high CASP4 expression are more prone to IFN-γ-induced pyroptosis than those with low CASP4 expression. Our findings indicate that the CASP4 level in primary lung adenocarcinoma can predict metastasis and responsiveness to high-dose IFN-γ therapy due to cancer cell pyroptosis.
Our findings indicate that the CASP4 level in primary lung adenocarcinoma can predict metastasis and responsiveness to high-dose IFN-γ therapy due to cancer cell pyroptosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Japan, Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913); Japan, Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913)
2 Japan, Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913)
3 Japan, Shared-Use Research Center, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913)
4 Japan, Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan (GRID:grid.271052.3) (ISNI:0000 0004 0374 5913)
5 Aichi Cancer Center Hospital, Department of Pathology and Molecular Diagnostics, Nagoya, Japan (GRID:grid.410800.d) (ISNI:0000 0001 0722 8444)
6 Aichi Cancer Center Research Institute, Division of Translational Oncoimmunology, Nagoya, Japan (GRID:grid.410800.d) (ISNI:0000 0001 0722 8444)
7 Teikyo University Mizonokuchi Hospital, Department of Surgery, Kawasaki, Japan (GRID:grid.264706.1) (ISNI:0000 0000 9239 9995)